SwanBio Therapeutics
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 Monument Rd, Bala Cynwyd, Pennsylvan...Phone Number
(610) 557-0600Website
www.swanbiotx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About SwanBio Therapeutics
SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske, D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20 years of experience to the SwanBio Therapeutics team, most recently serving as the CMO at Achillion Pharmaceuticals, a clinical stage company focused on complement inhibitors, and at UniQure, a clinical stage gene therapy company focused on genetic diseases.Explore more
SwanBio Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SwanBio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at SwanBio Therapeutics
Earning: See what the market has to say on SwanBio Therapeutics recently announced quarterly report
Check out if SwanBio Therapeutics is spiking on competitors!
Product Launch: Get notified when SwanBio Therapeutics launches new products
Funding: Get notified immidiatlly once SwanBio Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check if SwanBio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
SwanBio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if SwanBio Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at SwanBio Therapeutics
Find 2 more new buyers
Compare Similar Companies to SwanBio Therapeutics
Compare insights from companies similar to SwanBio Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
$555M
2018
PR
Paul ReinfeldsSenior Vice President - Legal Affairs and General Counsel
Company Profile Activity
Activity Insights
SwanBio Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SwanBio Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SwanBio Therapeutics.
SwanBio Therapeutics financials insights
Gather financial insights about SwanBio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$52M
2022
Series B
$56M
SwanBio Therapeutics Tech Stack
A closer look at the technologies used by SwanBio Therapeutics
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Lateral Move
Executive Move
Board of Directors
Executive Move
Board of Directors
New Hire
Executive Move
Executive Move
Board of Directors
SwanBio Therapeutics News & Media
SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy
PHILADELPHIA--(BUSINESS WIRE)--SwanBio Therapeutics, a gene therapy company developing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today announced it has begun the second dose-escalation cohort of its first interventional clinical study, PROPEL. PROPEL is a Phase 1/2 first-in-human clinical trial assessing the safety and efficacy of SBT101, an investigational gene therapy designed to compensate for the ABCD1 mutation that causes adrenomyeloneuropathySwanBio Unveils Research in Next Generation CNS Capsids at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
PHILADELPHIA--(BUSINESS WIRE)--SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, presented preliminary data from primate studies of AAV capsids that outperform the commonly used AAV9 capsid. The findings illuminate SwanBio’s vector engineering capabilities and ongoing pursuit of novel capsids that deliver enhanced transgene expression, biodistribution, and safety profiles. “Our vector engineering platfSwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women
PHILADELPHIA--(BUSINESS WIRE)--SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women. “The real-world data we have gathered illuminate the under-acknowledged burden of AMN: affected individuals are experiencing more comorbidities, higher rates of hospitalization, substantially moSwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy
PHILADELPHIA--(BUSINESS WIRE)--SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today announced the initiation of its PROPEL clinical trial. The first-in-human trial will study the company’s lead candidate, SBT101, an investigational AAV-based gene therapy intended to treat the progressive and debilitating neurodegenerative disease adrenomyeloneuropathy (AMN). “As we wrap up a pivotal year for SwanBio
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SwanBio Therapeutics
Sign Up For FreeTo access detailed company insights
SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske, D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20 years of experien... Read More
